Program
emaretamig
Its studies are mostly in Adenocarcinoma, led by Astellas Pharma.
Furthest: phase 3, since Jun 23, 20263 company-led studies, 3 open or runningNext primary completion: Jan 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 33 open or running | phase 3since Jun 23, 2026 | May 5, 2022 | Jan 31, 2028phase 1 · NCT07024615 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2022First study: phase 1 study in AdenocarcinomaFirst studyNCT05365581 · 398 planned · United States, China, France and more
- Jun 9, 2025Phase 1 study in Pancreatic Ductal AdenocarcinomaNCT07024615 · 25 planned · United States
- Jun 23, 2026Phase 3 study in AdenocarcinomaPhase 3 reachedNCT07673887 · 570 planned · United States, China, Japan and more
Ahead
- Jan 31, 2028Primary completion: phase 1 study in Pancreatic Ductal AdenocarcinomaNCT07024615
- May 31, 2028Primary completion: phase 1 study in AdenocarcinomaNCT05365581
- Feb 28, 2031Primary completion: phase 3 study in AdenocarcinomaNCT07673887
TargetBeta
“A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07673887Adenocarcinoma · United States, China, Japan and more | 3 | Recruiting | Feb 28, 2031 | 570 |
| NCT07024615Pancreatic Ductal Adenocarcinoma · United States | 1 | Recruiting | Jan 31, 2028 | 25 |
| NCT05365581Adenocarcinoma · United States, China, France and more | 1 | Recruiting | May 31, 2028 | 398 |
How it is read
Names in the registry
- “ASP2138”, 3 entries
Conditions, from the studies’ own filings
- Adenocarcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.